This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- Pfizer (PFE) raised its full-year revenue and profit guidance after beating Q3 estimates, driven by strong performance across its product portfolio.
- Eaton (ETN) reported a significant earnings beat and hiked its 2026 outlook, signaling robust demand in its electrical and aerospace segments.
- Marathon Petroleum (MPC) authorized a new $5 billion share buyback program following a Q3 earnings beat that saw adjusted EPS reach $26.93.
- BioNTech (BNTX) narrowed its full-year revenue guidance upward after reporting a surprise quarterly profit of €1.76 per share.
- Apollo Global Management (APO) saw its total Assets Under Management (AUM) climb to $1.07 trillion, though adjusted net income slightly missed analyst estimates.
The third-quarter earnings season continued with a flurry of reports from major industry leaders, largely characterized by upward guidance revisions and resilient consumer demand. Pfizer (PFE) stood out by raising its full-year revenue target to a range of $62.0 billion to $64.0 billion, up from its previous forecast. The pharmaceutical giant reported adjusted EPS of $0.87, comfortably ahead of the $0.73 consensus.
Eaton (ETN) demonstrated the ongoing strength of the industrial sector, reporting net sales of $8.95 billion. The company’s Electrical Americas division was a primary driver of growth, outperforming estimates with $4.17 billion in sales. Consequently, Eaton raised its full-year adjusted EPS guidance to a midpoint of $13.75, reflecting optimism regarding infrastructure and data center demand.
In the energy sector, Marathon Petroleum (MPC) delivered an adjusted EBITDA of $11.7 billion, surpassing the $10.93 billion expected by analysts. Beyond the earnings beat, the company’s board approved an incremental $5 billion for share repurchases. Management also projected lower-than-expected direct operating costs for the fourth quarter at $5.60 per barrel.
BioNTech (BNTX) surprised the market with a quarterly revenue of €1.29 billion, significantly higher than the €1.02 billion estimate. The company now expects full-year revenue to land between €1.70 billion and €1.90 billion. While R&D expenses remain high at up to €2.30 billion, the quarterly operating income of €125 million signals a stabilization in the post-pandemic biotech landscape.
Luxury automaker Ferrari (RACE) and beverage giant Keurig Dr Pepper (KDP) both met or slightly exceeded expectations. Ferrari reported a revenue of €1.90 billion and EBITDA of €753 million, supported by 3,368 vehicle deliveries. Meanwhile, Keurig Dr Pepper reaffirmed its 2026 guidance, posting net sales of $7.34 billion and benefiting from steady pricing power in the North American market.
In the financial services sector, Apollo Global Management (APO) reported record loan originations despite debt-market turbulence. While its adjusted net income of $2.15 per share was just shy of the $2.19 estimate, its fee-related earnings grew to $802 million. Similarly, Italy's Intesa Sanpaolo raised its net income outlook to "well above" €10 billion, citing stronger-than-anticipated net interest income.
Finally, a Reuters Poll of FX strategists suggests a strengthening US Dollar in the near term. The Euro is forecasted to trade at $1.13 in three months, a downward revision from previous polls. A majority of strategists believe the dollar is more likely to trade stronger than current expectations over the next quarter due to shifting interest rate outlooks.
Automated market updates written with AI from market data and news wire reports, published without human review.